Chronicling the COPD Patient Journey and change in COPD symptoms, quality of life and exacerbations following initiation of Budenoside/Glycopyrronium/Formoterol [BGF] - CHRONICLES

Study identifier:D5980R00105

ClinicalTrials.gov identifier:NCT06511193

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

Chronicling the COPD Patient Journey and change in impact of a single inhaler combination therapy on COPD symptoms, quality of life and exacerbations following initiation of Budenoside/Glycopyrronium/Formoterol [BGF](CHRONICLES COPD)

Medical condition

Chronic obstructive pulmonary disease (COPD)

Phase

Phase 4

Healthy volunteers

No

Study drug

Budenoside/Glycopyrronium/Formoterol

Sex

All

Estimated Enrollment

200

Study type

Observational

Age

35 Years - 130 Years

Date

Study Start Date: 30 Aug 2024
Estimated Primary Completion Date: 29 Aug 2025
Estimated Study Completion Date: 29 Aug 2025

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Asthma Research Group Inc., University Health Network

Inclusion and exclusion criteria